Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Parallel-controlled, Exploratory Clinical Trial of Second-line Chemotherapy With Second-line Chemotherapy Versus Second-line Chemotherapy With Apatinib in the Treatment of Metastatic Colorectal Cancer

NCT03412994 is registered in ClinicalTrials.gov with Liqiang Zhong as lead sponsor.

NCT NCT03412994
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03412994 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Parallel-controlled, Exploratory Clinical Trial of Second-line Chemotherapy With Second-line Chemotherapy Versus Second-line Chemotherapy With Apatinib in the Treatment of Metastatic Colorectal Cancer
Lead sponsor
Liqiang Zhong
Phase
Phase 2
Overall status
Unknown status
Start date
February 28, 2018
Completion date
February 28, 2021
Enrollment
60 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal neoplasms